Irv Weissman, Stanford

PD-L1, CD47 and now CD24? Star Stan­ford I/O sci­en­tist Irv Weiss­man points to a ‘ma­jor’ new can­cer tar­get

Famed Stan­ford drug re­searcher Irv Weiss­man, who helped set off a scram­ble to de­vel­op new drugs that can si­lence the “don’t eat me” sig­nal sent by CD47, says he and a team of in­ves­ti­ga­tors in his lab have found a com­ple­men­tary tar­get on the menu that promis­es to work where the pi­o­neer­ing drugs fall far short of the mark.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA